

1 **Vitamin D, chronic pain, and depression: linear and non-linear**
2 **Mendelian randomization analyses**

3 Emily Bassett¹, Eva Gjekmarkaj², Amy M. Mason³, Sizheng Steven Zhao^{4*}, Stephen Burgess^{1,3*†}

4

- 5 1. MRC Biostatistics Unit, University of Cambridge, Cambridge, CB2 0SR, United Kingdom.
6 2. Department of Public Health and Primary Care, University of Cambridge, Strangeways
7 Research Laboratory, Cambridge, CB1 8RN, United Kingdom.
8 3. British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and
9 Primary Care, University of Cambridge, Cambridge, CB2 0BD, United Kingdom.
10 4. Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological
11 Science, School of Biological Sciences, Faculty of Biological Medicine and Health, University
12 of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

13

14 * These authors contributed equally to this work.

15 † Corresponding author: Stephen Burgess, MRC Biostatistics Unit, East Forvie Building, Robinson
16 Way, Cambridge CB2 0SR. Telephone: 01223 768259. Email: sb452@medschl.cam.ac.uk.

17

18 **Running title:** Vitamin D, chronic pain, and depression (39 characters)

19 **ABSTRACT**

20 Vitamin D deficiency has been linked to various chronic pain conditions. However, randomized trials
21 of vitamin D supplementation have had mixed results. In contrast, systematic reviews of randomized
22 trials indicate a protective effect of vitamin D supplementation on depression. We undertake a
23 Mendelian randomization investigation in UK Biobank, a study of UK residents aged 40-65 at
24 recruitment. We perform linear and non-linear Mendelian randomization analyses for four
25 outcomes: fibromyalgia, clinical fatigue, chronic widespread pain, and probable lifetime major
26 depression. We use genetic variants from four gene regions with known links to vitamin D biology as
27 instruments. In linear analyses, genetically-predicted levels of 25-hydroxyvitamin D [25(OH)D], a
28 clinical marker of vitamin D status, were not associated with fibromyalgia (odds ratio [OR] per 10
29 nmol/L higher 25(OH)D 1.02, 95% confidence interval [CI] 0.93, 1.12), clinical fatigue (OR 0.99, 95%
30 CI 0.94, 1.05), chronic widespread pain (OR 0.95, 95% CI 0.89, 1.02), or probable lifetime major
31 depression (OR 0.97, 95% CI 0.93, 1.01). In non-linear analyses, an association was observed
32 between genetically-predicted 25(OH)D levels and depression in the quintile of the population with
33 the lowest 25(OH)D levels (OR 0.78, 95% CI 0.64, 0.94); associations were null in other strata. Our
34 findings suggest that population-wide vitamin D supplementation will not substantially reduce pain
35 or depression; however, targeted supplementation of deficient individuals may reduce risk of
36 depression.

37 INTRODUCTION

38 Vitamin D deficiency, defined as low levels of circulating 25-hydroxyvitamin D (25(OH)D)¹, has been
39 linked to recurrent and chronic pain conditions. Profound vitamin D deficiency is strongly linked to
40 pain from osteomalacia, a bone weakening disorder². Low vitamin D levels have also been suggested
41 to play a role in the aetiology of chronic pain states through their influence on bone biology,
42 autoimmune diseases, inflammation, or neuromuscular and other immunological influences on pain
43 manifestation^{3,4}. Empirical evidence from observational studies indicates hypovitaminosis D to be
44 highly prevalent in patients with chronic pain⁵, fibromyalgia⁶, and depression⁷.

45 However, evidence for a direct causal link between low 25(OH)D levels and chronic pain conditions is
46 incomplete. Randomized controlled trials examining the impact of vitamin D supplements as a
47 treatment for chronic pain conditions such as fibromyalgia are limited in size and quality^{8,9}. In
48 contrast, systematic reviews of randomized trials for depression¹⁰, depressive symptoms^{11,12}, and
49 negative emotions¹³ have indicated beneficial effects of vitamin D supplementation, although no
50 evidence for an effect was observed in the large Vitamin D and Omega-3 Trial (VITAL)¹⁴. Inverse
51 associations have also been observed in observational epidemiological studies¹⁵⁻¹⁷, although such
52 investigations are vulnerable to bias from confounding and reverse causality: individuals with
53 depression could have low vitamin D levels due to spending less time outdoors or changes in
54 appetite and diet.

55 An alternative approach to randomized controlled trials that addresses the issues of confounding
56 and reverse causality is Mendelian randomization. Genetic variants having a specific association with
57 circulating 25(OH)D levels can be used as unconfounded proxies for changes in 25(OH)D levels to
58 assess the likelihood of a causal link between vitamin D and chronic pain conditions. As genetic
59 variants are randomly distributed at conception, they are unlikely to be related to possible
60 confounders¹⁸. In addition, chronic pain conditions cannot affect the genotype and so reverse
61 causality is avoided¹⁹. As a result, Mendelian randomization analyses can provide more reliable
62 insights into any potential causal relationship between vitamin D and chronic pain conditions
63 compared with conventional observational studies. As the shape of the relationship between
64 25(OH)D serum levels and chronic pain conditions is unknown, and many observational vitamin D
65 studies have shown a threshold effect⁵ – where the disease risks are only related to the people with
66 vitamin D deficiency – the standard Mendelian randomization approach which assumes linearity may
67 overlook non-linear effects of 25(OH)D.

68 Given the uncertainty in the empirical literature as to the nature of the relationship between vitamin
69 D serum levels and chronic pain conditions, we investigated evidence for a causal effect of 25(OH)D
70 concentrations on chronic pain outcomes. We used individual-level data from the UK Biobank study
71 to perform both linear and non-linear Mendelian randomization analyses. We also considered
72 depression as an additional outcome, to validate trial findings and investigate the evidence for a
73 causal effect on this outcome both in the population as a whole, and for strata of the population to
74 assess the shape of any potential effect.

75 **SUBJECTS AND METHODS**

76 **Study population**

77 The UK Biobank cohort comprises around 500,000 participants aged 40 to 69 years at baseline,
78 recruited between 2006-2010 at 22 assessment centres throughout the UK, and followed up for a
79 variety of health conditions from their recruitment date until July 2019 or their date of death.
80 Informed consent was obtained from all participants. The dataset includes genome-wide genotyping
81 of baseline samples from all participants, results of clinical examinations, assays of biological
82 samples, detailed information on self-reported health behaviour, and is supplemented by linkage
83 with electronic health records such as hospital inpatient data, mortality data, and cancer registries²⁰.

84 We restricted our attention to 333,025 unrelated participants of European ancestry that passed
85 various quality control tests and had a valid 25(OH)D measurement. European ancestry was defined
86 using self-reported ethnicity and genomic principal components as described previously²¹. We
87 removed related individuals so that only one person in each family (defined as third-degree relatives
88 or closer) was included in the analysis.

89 **Vitamin D measurement and classification**

90 Concentrations of 25(OH)D in blood were measured using the DiaSorin Liaison immunoassay
91 analyser. Measurements were mean-shifted to correspond to a measurement taken in October, in
92 order to account for seasonal variability in 25(OH)D concentrations.

93 **Outcomes**

94 We considered four outcomes: fibromyalgia, clinical fatigue, chronic widespread pain, and probable
95 lifetime major depression.

96 Fibromyalgia was defined as ICD-9 code 729.1, ICD-10 code M79.7, or self-reported code (field
97 20002) 1542. Clinical fatigue was defined as ICD-9 code 780.7, ICD-10 code R53, or self-reported
98 code 1482. Chronic widespread pain was defined as answering yes to the four questions “Have you
99 had pain for more than 3 months?” relating to the neck or shoulder (field 3404), back (field 3571),
100 hip (field 3414), and knees (field 3773).

101 Probable lifetime major depression was defined as the presence of four criteria²²: 1) answering yes
102 to the question “Looking back over your life, have you ever had a time when you were feeling
103 depressed or down for at least a whole week?” or “Have you ever had a time when you were

104 uninterested in things or unable to enjoy the things you used to for at least a whole week?”, 2)
105 answering 2 weeks or more to the question “How many weeks was the longest period when you
106 were feeling depressed or down?”, 3) answering 2 or more to the question “How many periods have
107 you had when you were feeling depressed or down for at least a whole week?”, 4) answering yes to
108 the question “Have you ever seen a general practitioner for nerves, anxiety, tension or depression?”
109 or “Have you ever seen a psychiatrist for nerves, anxiety, tension or depression?”.

110 **Genetic variants**

111 To minimize potential bias due to horizontal pleiotropy, we took genetic variants from four gene
112 regions previously shown to be strongly associated with 25(OH)D and implicated in the transport,
113 metabolism, and synthesis of vitamin D²³ – *GC*, *DHCR7*, *CYP2R1*, and *CYP24A1*. The *GC* gene encodes
114 vitamin D binding protein. The *DHCR7* gene product converts 7-dehydrocholesterol to cholesterol,
115 reducing 7-dehydrocholesterol available for conversion to previtamin D₃ by solar radiation. The
116 *CYP2R1* gene encodes vitamin D 25-hydroxylase, a regulator of 25(OH)D synthesis through 25-
117 hydroxylation of vitamin D in the liver. The *CYP24A1* gene product inactivates the active form of
118 vitamin D (1 α 25(OH)₂D).

119 To maximize the variance explained by the genetic instrument, we considered available variants at
120 each genetic locus, and selected variants associated with 25(OH)D concentrations using a stepwise
121 selection method²⁴. In total, 21 variants were included in the analysis (Supplementary Table 1). We
122 constructed an allelic score weighting variants by their conditional associations with 25(OH)D
123 concentration.

124 **Statistical analyses**

125 *Linear analyses*

126 Linear Mendelian randomization estimates were calculated using the ratio method by dividing the
127 genetic association with the outcome by the genetic association with 25(OH)D concentration, and
128 scaling the estimate to a 10 nmol/L difference in genetically-predicted 25(OH)D concentration.

129 Genetic associations were estimated using logistic regression for disease outcomes, and using linear
130 regression for 25(OH)D concentrations. All regression models were adjusted for age at baseline, sex,
131 centre, and ten genetic principal components of ancestry.

132 *Non-linear analyses*

133 Non-linear Mendelian randomization estimates were performed by first dividing the population into
134 five equal-sized strata using the doubly-ranked method²⁵. Estimates were then obtained in each
135 stratum as per the linear analyses. Secondary analyses were performed by dividing the population
136 into five equal-sized strata using the residual method for untransformed and log-transformed values
137 of 25(OH)D concentrations²⁶. The doubly-ranked method has been recommended for use with
138 25(OH)D concentrations, as in this case the genetic effect on the exposure is not constant in the
139 population; this assumption is made by the residual stratification method²⁷.

140 All statistical analyses were performed in R version 4.0.5.

141 **Ethics**

142 UK Biobank ethical approval is provided by the UK Biobank research ethics committee and Human
143 Tissue Authority research tissue bank. An independent Ethics and Governance Council oversees
144 adherence to the Ethics and Governance Framework and provides advice on the interests of
145 research participants and the general public in relation to UK Biobank. The current study was
146 approved by UK Biobank (ref no. 98032).

147 **RESULTS**

148 **Study population**

149 A summary of participant characteristics is presented in Table 1. The mean age of participants was
150 57.1 years, and 53.4% of participants were female. Mean 25(OH)D concentration (mean-shifted to
151 correspond to an October measurement) was 55.4 nmol/L. 2424 participants (0.7%) had
152 fibromyalgia, 6764 (2.0%) had clinical fatigue, 4279 (1.3%) had chronic widespread pain, and 13,125
153 (3.9%) had probable lifetime major depression. The genetic instrument explained 4.7% of the
154 variance in 25(OH)D levels, corresponding to an F statistic of 745.

155 **Linear analyses**

156 Linear Mendelian randomization estimates, representing the odds ratio for the average association
157 with the outcome for 10 nmol/L higher genetically-predicted 25(OH)D in the whole population, are
158 provided in Table 2. Estimates were 1.02 (95% confidence interval [CI]: 0.93, 1.12; $p = 0.65$) for
159 fibromyalgia, 0.99 (95% CI: 0.94, 1.05; $p = 0.86$) for clinical fatigue, 0.95 (95% CI: 0.89, 1.02; $p = 0.18$)
160 for chronic widespread pain, and 0.97 (95% CI: 0.93, 1.01; $p = 0.18$) for probable lifetime major
161 depression.

162 **Non-linear analyses**

163 Non-linear Mendelian randomization estimates, representing the odds ratio for the average
164 association with the outcome for 10 nmol/L higher genetically-predicted 25(OH)D in each stratum of
165 the population, are provided in Figure 1. As stratification is based on the exposure, the participants
166 in each of the five strata (and hence the stratum-specific mean levels of 25(OH)D) are the same for
167 each outcome. Associations were null in each stratum with the exception of chronic widespread pain
168 in the stratum with the highest mean 25(OH)D levels (0.89, 95% CI: 0.80, 0.99; $p=0.026$), and
169 probable lifetime major depression in the stratum with the lowest mean 25(OH)D levels (0.78, 95%
170 CI: 0.64, 0.94; $p = 0.009$). A similar inverse association for probable lifetime major depression in this
171 stratum was detected using the residual method for both untransformed and log-transformed
172 25(OH)D levels (Supplementary Table 2).

173 **DISCUSSION**

174 We conducted one-sample Mendelian randomization analyses in UK Biobank using both linear and
175 non-linear methods. We did not observe associations between genetically-predicted 25(OH)D and
176 various outcomes in the population as a whole, suggesting that population shifts in vitamin D levels
177 will not substantially decrease risk of fibromyalgia, clinical fatigue, chronic widespread pain, or
178 probable lifetime major depression. However, we did observe an association with probable lifetime
179 major depression in the stratum of the population with the lowest levels of 25(OH)D. This suggests
180 that vitamin D supplementation may reduce risk of depression for those with low vitamin D levels.

181 Our findings may clarify evidence found in clinical trials for the effect of vitamin D supplementation
182 on depression. While recent meta-analyses of randomized controlled trials of vitamin D
183 supplementation have found evidence for reductions in depression and depressive symptoms¹¹⁻¹³,
184 the VITAL trial did not observe any reduction in risk¹⁴. However, few individuals in the VITAL trial had
185 deficient levels of vitamin D. Additionally, VITAL trial participants were allowed to continue taking
186 low dose vitamin D supplements, even if they were assigned to the placebo arm of the trial. Our
187 findings suggest that any benefit of vitamin D supplementation may be limited to those with low
188 vitamin D levels, and that supplementation beyond a threshold level may provide limited additional
189 benefit. This corresponds to what has been seen in supplementation trials for acute respiratory tract
190 infections, which have reported stronger evidence of risk reduction in those with 25(OH)D
191 concentrations below 25 nmol/L²⁸. Similarly, a previous systematic review of trials found that
192 evidence of an inverse effect of vitamin D supplementation was limited to studies in those with
193 deficient vitamin D levels at baseline²⁹. This is also supported by research suggesting that vitamin D
194 deficiency precedes the development of depression rather than being associated with its effects³⁰.

195 We did not observe evidence suggesting any effect of vitamin D supplementation on fibromyalgia,
196 clinical fatigue, or chronic widespread pain, beyond a slight protective association in one stratum
197 that may represent a chance finding. This may be due to lack of power, as the number of cases for
198 these outcomes was less than that for depression. Another challenge is defining these outcomes, as
199 these conditions are not always accurately captured in routinely-collected healthcare records.

200 While our findings suggest that population-wide vitamin D supplementation will not substantially
201 reduce risk of depression, they suggest vitamin D supplementation may reduce risk of depression for
202 those with insufficient vitamin D levels. For any future clinical trials of vitamin D supplementation,
203 this reinforces the importance of recruiting enough patients with vitamin D deficiency at baseline, so

204 the trial has enough statistical power to detect an effect in deficient individuals³¹. However,
205 recruiting enough vitamin D deficient individuals into such a trial to attain adequate power, and
206 ensuring that those assigned to the placebo group do not self-medicate, may prove challenging in
207 practice.

208 A number of different biological mechanisms might explain the direct relationship observed
209 between low levels of circulating 25(OH)D and probable lifetime major depression. Inflammation is
210 proposed to play a causal role in the development of depression^{32,33}, and vitamin D has been
211 observed to play an anti-inflammatory role in neurological functioning by preventing oxidative
212 damage to nervous tissue³⁴. It has also been suggested in several randomized controlled trials that
213 higher vitamin D levels result in lower levels of inflammatory cytokines³⁵. There is also evidence that
214 vitamin D plays a neuroprotective role in the proliferation, differentiation, survival and growth of
215 neurons³⁶. Recent studies in mice also indicate that a lack of vitamin D might influence microbiome
216 diversity related to mood disorders³⁷, in line with recent research into the role of gut microbiome in
217 depression³⁸. Finally, in vitro work has also suggested a connection between vitamin D and the
218 hypothalamic–pituitary–adrenal (HPA) axis via influence on the glucocorticoid receptors³⁹, which has
219 a known role in the development of depression⁴⁰. Given the number of biological pathways through
220 which vitamin D levels might play a role in risk of depression, this may explain the associations we
221 found between lower genetically-predicted 25(OH)D levels and probable lifetime major depression
222 but not chronic pain conditions.

223 Our investigation has strengths in the Mendelian randomization design, large sample size, and
224 biologically-driven choice of genetic variants. However, there are also potential limitations. Our
225 analysis was restricted to individuals with European ancestry. This limits the validity and applicability
226 of the findings, particularly as individuals with darker skin have lower 25(OH)D levels. Mendelian
227 randomization analyses make the assumption that the only causal pathway from the genetic variants
228 to the outcome is via the exposure. While the four gene regions chosen for this study have strong
229 biological links to vitamin D, this assumption cannot be tested empirically. Further, even if the
230 Mendelian randomization assumptions are satisfied, genetic variants may influence 25(OH)D
231 concentrations in a different way to dietary supplementation or other clinical interventions. We
232 used the doubly-ranked method for non-linear Mendelian randomization, which is more robust than
233 the residual method, but some residual bias owing to variability in the genetic effects on the
234 exposure may remain²⁷. Our outcome definitions are likely to have missed some cases; we only
235 identified around 4% of UK Biobank participants as having depression, whereas lifetime prevalence

236 of major depression is around 10-20% according to general population studies⁴¹. Misclassification of
237 cases as controls generally introduces a bias towards the null, so the genetic associations observed
238 in our analysis are likely to be conservative, and hence may underestimate the true impact on
239 disease risk.

240 In conclusion, we found evidence for an effect of vitamin D on depression in individuals with low
241 vitamin D status, but no evidence of an effect at any level of 25(OH)D for other pain outcomes.

242 **ACKNOWLEDGEMENTS**

243 SSZ is supported by a National Institute for Health Research Clinical Lectureship and works in centres
244 supported by Versus Arthritis (grant no. 21173, 21754 and 21755). SB is supported by the Wellcome
245 Trust (225790/Z/22/Z) and the United Kingdom Research and Innovation Medical Research Council
246 (MC_UU_00002/7). This research was supported by the National Institute for Health Research
247 Cambridge Biomedical Research Centre (NIHR203312). The views expressed are those of the authors
248 and not necessarily those of the National Institute for Health Research or the Department of Health
249 and Social Care.

250 **CONFLICTS OF INTEREST**

251 The authors declare no conflict of interest.

252 **SUPPLEMENTARY INFORMATION**

253 Supplementary information is available at Molecular Psychiatry's website

REFERENCES

1. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. *Ann Epidemiol* 2009; **19**(2): 73-78.
2. Christodoulou S, Goula T, Ververidis A, Drosos G. Vitamin D and bone disease. *Biomed Res Int* 2013; **2013**: 396541.
3. Wintermeyer E, Ihle C, Ehnert S, Stöckle U, Ochs G, de Zwart P *et al.* Crucial Role of Vitamin D in the Musculoskeletal System. *Nutrients* 2016; **8**(6).
4. Eyles DW, Burne TH, McGrath JJ. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. *Front Neuroendocrinol* 2013; **34**(1): 47-64.
5. Helde-Frankling M, Björkhem-Bergman L. Vitamin D in Pain Management. *Int J Mol Sci* 2017; **18**(10).
6. Karras S, Rapti E, Matsoukas S, Kotsa K. Vitamin D in Fibromyalgia: A Causative or Confounding Biological Interplay? *Nutrients* 2016; **8**(6).
7. Milaneschi Y, Hoogendijk W, Lips P, Heijboer AC, Schoevers R, van Hemert AM *et al.* The association between low vitamin D and depressive disorders. *Mol Psychiatry* 2014; **19**(4): 444-451.
8. Shipton EE, Shipton EA. Vitamin D Deficiency and Pain: Clinical Evidence of Low Levels of Vitamin D and Supplementation in Chronic Pain States. *Pain Ther* 2015; **4**(1): 67-87.
9. Straube S, Derry S, Moore RA, McQuay HJ. Vitamin D for the treatment of chronic painful conditions in adults. *Cochrane Database Syst Rev* 2010; (1): Cd007771.
10. Vellekkatt F, Menon V. Efficacy of vitamin D supplementation in major depression: A meta-analysis of randomized controlled trials. *J Postgrad Med* 2019; **65**(2): 74-80.
11. Musazadeh V, Keramati M, Ghalichi F, Kavyani Z, Ghoreishi Z, Alras KA *et al.* Vitamin D protects against depression: Evidence from an umbrella meta-analysis on interventional and observational meta-analyses. *Pharmacol Res* 2023; **187**: 106605.
12. Mikola T, Marx W, Lane MM, Hockey M, Loughman A, Rajapolvi S *et al.* The effect of vitamin D supplementation on depressive symptoms in adults: A systematic review and meta-analysis of randomized controlled trials. *Crit Rev Food Sci Nutr* 2022: 1-18.
13. Cheng Y-C, Huang Y-C, Huang W-L. The effect of vitamin D supplement on negative emotions: A systematic review and meta-analysis. *Depress Anxiety* 2020; **37**(6): 549-564.
14. Okereke OI, Reynolds CF, 3rd, Mischoulon D, Chang G, Vyas CM, Cook NR *et al.* Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. *JAMA* 2020; **324**(5): 471-480.
15. Anglin RE, Samaan Z, Walter SD, McDonald SD. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. *Br J Psychiatry* 2013; **202**: 100-107.
16. Hoang MT, Defina LF, Willis BL, Leonard DS, Weiner MF, Brown ES. Association between low serum 25-hydroxyvitamin D and depression in a large sample of healthy adults: the Cooper Center longitudinal study. *Mayo Clin Proc* 2011; **86**(11): 1050-1055.

17. Almeida OP, Hankey GJ, Yeap BB, Golledge J, Flicker L. Vitamin D concentration and its association with past, current and future depression in older men: The Health In Men Study. *Maturitas* 2015; **81**(1): 36-41.
18. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet* 2014; **23**(R1): R89-R98.
19. Burgess S, Swanson SA, Labrecque JA. Are Mendelian randomization investigations immune from bias due to reverse causation? *Eur J Epidemiol* 2021; **36**(3): 253-257.
20. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J *et al.* UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLOS Med* 2015; **12**(3): e1001779.
21. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL *et al.* The allelic landscape of human blood cell trait variation and links to common complex disease. *Cell* 2016; **167**(5): 1415-1429.
22. Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J *et al.* Prevalence and characteristics of probable major depression and bipolar disorder within UK biobank: cross-sectional study of 172,751 participants. *PLOS One* 2013; **8**(11): e75362.
23. Mokry LE, Ross S, Ahmad OS, Forgetta V, Smith GD, Leong A *et al.* Vitamin D and risk of multiple sclerosis: a Mendelian randomization study. *PLOS Med* 2015; **12**(8): e1001866.
24. Sofianopoulou E, Kaptoge SK, Afzal S, Jiang T, Gill D, Gundersen TE *et al.* Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses. *Lancet Diabetes Endocrinol* 2021; **9**(12): 837-846.
25. Tian H, Mason AM, Liu C, Burgess S. Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. *bioRxiv* 2022: 2022.2006.2028.497930.
26. Burgess S, Davies NM, Thompson SG. Instrumental variable analysis with a nonlinear exposure-outcome relationship. *Epidemiology* 2014; **25**(6): 877-885.
27. Burgess S. Violation of the constant genetic effect assumption can result in biased estimates for non-linear Mendelian randomization. *medRxiv* 2022: 2022.2010.2026.22280570.
28. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P *et al.* Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *BMJ* 2017; **356**: i6583.
29. Spedding S. Vitamin D and depression: a systematic review and meta-analysis comparing studies with and without biological flaws. *Nutrients* 2014; **6**(4): 1501-1518.
30. Ronaldson A, Arias de la Torre J, Gaughran F, Bakolis I, Hatch SL, Hotopf M *et al.* Prospective associations between vitamin D and depression in middle-aged adults: findings from the UK Biobank cohort. *Psychol Med* 2022; **52**(10): 1866-1874.
31. Ala-Korpela M. The epidemiological quest for the role of vitamin D turned non-linear—and simply made sense. *Int J Epidemiol* 2022: dyac218.
32. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat Rev Immunol* 2016; **16**(1): 22-34.

33. Ye Z, Kappelmann N, Moser S, Davey Smith G, Burgess S, Jones PB *et al.* Role of inflammation in depression and anxiety: Tests for disorder specificity, linearity and potential causality of association in the UK Biobank. *eClinicalMedicine* 2021; **38**.
34. Wrzosek M, Łukasziewicz J, Wrzosek M, Jakubczyk A, Matsumoto H, Piątkiewicz P *et al.* Vitamin D and the central nervous system. *Pharmacol Rep* 2013; **65**(2): 271-278.
35. Cannell JJ, Grant WB, Holick MF. Vitamin D and inflammation. *Dermatoendocrinol* 2014; **6**(1): e983401.
36. Groves NJ, Burne THJ. The impact of vitamin D deficiency on neurogenesis in the adult brain. *Neural Regen Res* 2017; **12**(3): 393-394.
37. Jin D, Wu S, Zhang YG, Lu R, Xia Y, Dong H *et al.* Lack of Vitamin D Receptor Causes Dysbiosis and Changes the Functions of the Murine Intestinal Microbiome. *Clin Ther* 2015; **37**(5): 996-1009.e1007.
38. Winter G, Hart RA, Charlesworth RPG, Sharpley CF. Gut microbiome and depression: what we know and what we need to know. *Rev Neurosci* 2018; **29**(6): 629-643.
39. Obradovic D, Gronemeyer H, Lutz B, Rein T. Cross-talk of vitamin D and glucocorticoids in hippocampal cells. *J Neurochem* 2006; **96**(2): 500-509.
40. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. *Trends Neurosci* 2008; **31**(9): 464-468.
41. Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of Depression in the Community from 30 Countries between 1994 and 2014. *Sci Rep* 2018; **8**(1): 2861.

Table 1: Participant characteristics for the analytic sample from UK Biobank

	UK Biobank
Participants	333 025
Age at baseline	57.1 ± 8.1
Sex	
Female	177 745 (53.4)
Male	155 280 (46.6)
25(OH)D concentration (nmol/L)	55.4 ± 19.3
Fibromyalgia cases	2424 (0.7)
Clinical fatigue cases	6764 (2.0)
Chronic widespread pain cases	4279 (1.3)
Probable lifetime major depression cases	13 125 (3.9)
BMI (kg/m²)	27.3 ± 4.8
SBP (mmHg)	137.5 ± 18.6
Smoking	
Current	34 085 (10.2)
Other	298 940 (89.8)
Diabetes	
Known history	15 822 (4.8)
No known history	317 203 (95.2)

Values represent mean ± standard deviation for continuous traits or N (%) for categorical traits. 25(OH)D concentrations are season-shifted to correspond to a measurement taken in autumn.

Table 2. Linear Mendelian randomization estimates in the overall population

Outcome	Estimate	95% confidence interval	p-value
Fibromyalgia	1.02	0.93, 1.12	0.65
Clinical fatigue	0.99	0.94, 1.05	0.86
Chronic widespread pain	0.95	0.89, 1.02	0.18
Probable lifetime major depression	0.97	0.93, 1.01	0.18

Estimates represent odds ratios per 10 nmol/L higher genetically-predicted concentration of 25(OH)D in the overall population.

FIGURE CAPTION

Figure 1. Non-linear Mendelian randomization estimates in strata of the population

Caption: Concentrations are stratum-specific mean levels of 25(OH)D. Estimates (95% confidence intervals) represent odds ratios per 10 nmol/L higher genetically-predicted concentration of 25(OH)D in strata of the population defined using the doubly-ranked method.